Onconetix, inc. announces 1-for-40 reverse stock split and results of the annual meeting of stockholders

Cincinnati, ohio, sept. 20, 2024 (globe newswire) -- onconetix, inc. (nasdaq: onco) (“onconetix” or the “company”), a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology, today announced that the company's stockholders have approved all proposals voted on at the company's 2024 annual meeting of stockholders (the “annual meeting”) held on september 5, 2024, and that its board of directors (the “board of directors” or “board”) approved a 1-for-40 reverse stock split of its outstanding shares of common stock, to be effective as of 12:01 a.m. eastern time on tuesday, september 24, 2024.
ONCO Ratings Summary
ONCO Quant Ranking